Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARIANA A BAUER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1699062620
CMS profile
1009288
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$30.77

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $30.77 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
HydroCision, Inc. $16.45 1
SANOFI-AVENTIS U.S. LLC $14.32 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARIANA A BAUER

NPI 1699062620 · CMS profile ID 1009288

Allopathic & Osteopathic Physicians / Internal Medicine

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699062620?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARIANA A BAUER, NPI 1699062620, CMS profile ID 1009288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699062620?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ARIANA A BAUER, NPI 1699062620, CMS profile ID 1009288. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699062620?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ARIANA A BAUER, NPI 1699062620, CMS profile ID 1009288, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1699062620?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $30.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
HydroCision, Inc. $16.4505/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744322709 CMS
SANOFI-AVENTIS U.S. LLC $14.3202/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744101753 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $244.34 5
PY2020 $30.77 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $260,247.55 68
PY2024 Principal investigator $235,161.25 61
PY2023 Principal investigator $412,768.36 82
PY2022 Principal investigator $582,001.88 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,218.60 12/20/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163110
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $8,270.51 12/13/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189624
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $65.25 12/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189484
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $18,858.15 12/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189830
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $200.00 12/06/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189898
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $40.00 12/06/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189900
Principal investigator 1 SANOFI PASTEUR INC. $2,241.50 12/02/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703574
Principal investigator 1 SANOFI PASTEUR INC. $8,552.75 10/23/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703578
Principal investigator 1 SANOFI PASTEUR INC. $1,159.20 10/14/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703576
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $100.00 09/20/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189384
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $40.00 09/20/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189622
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,300.00 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163092
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163094
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163096
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163098
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163100
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $507.50 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189256
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $60.00 09/18/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189258
Principal investigator 1 Alnylam Pharmaceuticals Inc. $50.00 09/11/2024 Non-covered Recipient Entity
Quality Clinical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163090
Principal investigator 1 SANOFI US SERVICES INC. $796.50 09/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730550
Principal investigator 1 SANOFI US SERVICES INC. $1,372.29 08/14/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730548
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $100.00 08/07/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189482
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $40.00 08/07/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189728
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $100.00 08/07/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189730
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $7,000.63 08/07/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189828
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $30.00 08/07/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150190018
Principal investigator 1 SANOFI PASTEUR INC. $30,617.23 06/28/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703552
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,575.74 06/05/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189382
Principal investigator 1 SANOFI US SERVICES INC. $10,000.00 06/03/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730486
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 06/03/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730490
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 06/03/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730492
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 06/03/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730494
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 06/03/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) No dispute reported 06/30/2026 1128730496
Principal investigator 1 SANOFI PASTEUR INC. $2,835.18 05/23/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703550
Principal investigator 1 SANOFI PASTEUR INC. $1,505.00 05/22/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703546
Principal investigator 1 SANOFI US SERVICES INC. $280.00 05/08/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730488
Principal investigator 1 SANOFI PASTEUR INC. $3,421.10 04/24/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703548
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,187.41 04/01/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189826
Principal investigator 1 PFIZER INC. $4,410.00 03/29/2024 Non-covered Recipient Entity
Quality Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131031165
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $250.00 03/27/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189480
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $14,013.31 03/20/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150189620
Principal investigator 1 SANOFI PASTEUR INC. $210.00 03/18/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703534
Principal investigator 1 SANOFI PASTEUR INC. $33,119.84 03/18/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703536
Principal investigator 1 SANOFI PASTEUR INC. $14,761.82 03/18/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703542
Principal investigator 1 PFIZER INC. $1,500.00 03/15/2024 Non-covered Recipient Entity
Quality Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131031253
Principal investigator 1 SANOFI PASTEUR INC. $1,011.00 03/12/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703532
Principal investigator 1 SANOFI PASTEUR INC. $12,592.00 03/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703526
Principal investigator 1 SANOFI PASTEUR INC. $3,282.69 03/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703528
Principal investigator 1 SANOFI PASTEUR INC. $106.40 03/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703530
Principal investigator 1 SANOFI PASTEUR INC. $662.40 03/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703538
Principal investigator 1 SANOFI PASTEUR INC. $1,996.00 03/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703540
Principal investigator 1 SANOFI PASTEUR INC. $1,656.00 03/11/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128703544
Principal investigator 1 SANOFI US SERVICES INC. $5,514.75 02/28/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730484
Principal investigator 1 Bavarian Nordic A/S $1,500.00 02/21/2024 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663826
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $4,700.50 02/21/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
C3300-201 No dispute reported 06/30/2026 1150190016
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 02/16/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730478
Principal investigator 1 SANOFI US SERVICES INC. $500.00 02/16/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730480
Principal investigator 1 Bavarian Nordic A/S $130.00 02/13/2024 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663824
Principal investigator 1 SANOFI US SERVICES INC. $2,720.00 01/19/2024 Non-covered Recipient Entity
Quality Clinical Research Inc
A Multi-center, Multi-national, Prospective Surveillance Study of Respiratory Syncytial Virus Disease in Infants and Toddlers 6 to < 22 Months of Age No dispute reported 06/30/2026 1128730482
Principal investigator 1 PFIZER INC. $250.00 01/17/2024 Non-covered Recipient Entity
Quality Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131031312
Principal investigator 1 Bavarian Nordic A/S $750.00 01/09/2024 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 1119663822